您好，欢迎来到试剂信息网！ [登录] [免费注册]
试剂信息网
发布求购
位置：首页 > 产品库 > LLY507
立即咨询
咨询类型：
     
*姓名：
*电话：
*单位：
Email：
*留言内容：
请详细说明您的需求。
*验证码：
 
LLY507
本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。
LLY507图片
CAS NO:1793053-37-8
包装与价格：
包装价格(元)
10mg电议
50mg电议
500mg电议
1g电议

产品介绍
LLY507 是一种有效的选择性蛋白赖氨酸甲基转移酶 SMYD2 抑制剂。 LLY507 有效抑制 SMYD2 甲基化 p53 肽的能力，IC50 \u003c15 nM。 LLY507 作为一种有价值的化学探针，有助于剖析 SMYD2 在癌症和其他生物过程中的功能。
Cas No.1793053-37-8
化学名5-cyano-2'-(4-(2-(3-methyl-1H-indol-1-yl)ethyl)piperazin-1-yl)-N-(3-(pyrrolidin-1-yl)propyl)-[1,1'-biphenyl]-3-carboxamide
Canonical SMILESN#CC1=CC(C(NCCCN2CCCC2)=O)=CC(C3=CC=CC=C3N4CCN(CC4)CCN5C=C(C6=C5C=CC=C6)C)=C1
分子式C36H42N6O
分子量574.76
溶解度≥ 57.5mg/mL in DMSO
储存条件Store at -20°C
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

IC50:< 15 nM

LLY-507 is a potent inhibitor of SMYD2.

SMYD2, a lysine methyltransferase, catalyzes the monomethylation of several protein substrates including p53. SMYD2 is reported to be overexpressed in a significant percentage of esophageal squamous primary carcinomas, and such overexpression related with poor patient survival.

In vitro: LLY-507 has been identified as a cell-active, potent small molecule inhibitor of SMYD2. LLY-507 was found to be >100-fold selective for SMYD2 over a broad range of methyltransferase and non-methyltransferase targets. The crystal structure of SMYD2 in complex with LLY-507 showed it bound in the substrate peptide binding pocket. LLY-507 was active in cells as demonstrated by the reduction of SMYD2-induced monomethylation of p53 Lys(370) at submicromolar concentrations. Furthermore, MS-based proteomics indicated that cellular histone methylation levels were not affected by SMYD2 inhibition with LLY-507 significantly, and subcellular fractionation studies showed that SMYD2 was primarily cytoplasmic, indicating that SMYD2 targeted a small subset of histones. Moreover, LLY-507 was able to inhibit the proliferation of several liver, esophageal, as well as breast cancer cell lines in a dose-dependent manner [1].

In vivo: So far, there is no animal data reported.

Clinical trial: Up to now, LLY-507 is still in the preclinical development stage.

Reference:
[1] Nguyen H, et al.  LLY-507, a Cell-active, Potent, and Selective Inhibitor of Protein-lysine Methyltransferase SMYD2. J Biol Chem. 2015 May 29;290(22):13641-13653.